Speaking of controls and who wants to be one, here's an article on rethinking controls in new cancer meds trials.

"Controlled trials have for decades been considered essential for proving a drug’s value before it can go to market. But the continuing trial of the melanoma drug, PLX4032, has ignited an anguished debate among oncologists about whether a controlled trial that measures a drug’s impact on extending life is still the best method for evaluating hundreds of genetically targeted cancer drugs being developed. "

http://www.nytimes.com/2010/09/19/he...l.html?_r=1&hp